Infliximab (review) and adalimumab for the treatment of Crohn's disease: review update March 2015
Review of NICE Technology Appraisal Guidance No. 187; Infliximab and adalimumab for the treatment of Crohn's disease
TA187; Infliximab and adalimumab for the treatment of Crohn's disease, was added to the static list in 2011 following a review proposal consultation with relevant consultee and commentator organisations.
Following the recent publication of a NICE Evidence Update on Crohn’s disease, the Technology Appraisal programme has undertaken a consideration of a review of TA187 to assess whether an update of the guidance is necessary at this time.
We are satisfied that the newly available evidence would not lead to a material change in the existing recommendations. Consequently, we have decided that the recommendations from TA187 should remain on the static list and be incorporated into any future update of the clinical guideline for Crohn’s disease (CG152; Crohn's disease: Management in adults, children and young people).
The clinical guideline would be able to add context to the recommendations in order to address some of the issues that were raised in the Evidence Update. The clinical guideline would also be an appropriate place for evidence relating to these technologies outside of their existing marketing authorisations to be examined.
Topics on the static list can be considered for review at any time if new evidence comes to light that is likely to lead to a change in the existing recommendations.
This page was last updated: 13 March 2015